In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate
Objective(s): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mashhad University of Medical Sciences
2022-12-01
|
| Series: | Iranian Journal of Basic Medical Sciences |
| Subjects: | |
| Online Access: | https://ijbms.mums.ac.ir/article_21218_94249941c8ac4e5e7cdc9eeb993f2010.pdf |
| _version_ | 1797977643721687040 |
|---|---|
| author | Seyed Masih Adyani Hamid Rashidzadeh Mahdi Behdani Seyed Jamal Tabatabaei Rezaei Ali Ramazani |
| author_facet | Seyed Masih Adyani Hamid Rashidzadeh Mahdi Behdani Seyed Jamal Tabatabaei Rezaei Ali Ramazani |
| author_sort | Seyed Masih Adyani |
| collection | DOAJ |
| description | Objective(s): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time and safety. Materials and Methods: The synthesis process of the nanosystem has been characterized by different analytical methods. Results: The prepared nanoplatform exhibited high drug loading capacity, excellent colloidal stability, and an average particle size of around 105 nm. MTX was successfully conjugated through ester bonds and its release profile clearly showed that the ester bond is in favor of releasing the drug in acidic pH (5.5). The cytotoxicity of the developed nanoplatform exhibited great anti-cancer activity against MCF7 and KDR293 (cells with overexpressed anti-VEGFR2 NB receptors) cell lines while no deleterious toxicity was observed for nanocarrier against HEK293 normal cells. Furthermore, both hemolysis and LD50 assay results confirmed the hemocompatibility and biocompatibility of the developed nanoplatform. Conclusion: The most striking result to derive from the data is that the designed nanoplatform could potentially inhibit cell migration and invasion and the anti-angiogenesis properties of the developed nanoplatform may serve as a promising nanosystem to suppress the formation of blood vessels around tumor cells and consequently inhibit tumor progression. |
| first_indexed | 2024-04-11T05:11:17Z |
| format | Article |
| id | doaj.art-df819de7170c4639896dbc44f62b5387 |
| institution | Directory Open Access Journal |
| issn | 2008-3866 2008-3874 |
| language | English |
| last_indexed | 2024-04-11T05:11:17Z |
| publishDate | 2022-12-01 |
| publisher | Mashhad University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Basic Medical Sciences |
| spelling | doaj.art-df819de7170c4639896dbc44f62b53872022-12-25T11:14:14ZengMashhad University of Medical SciencesIranian Journal of Basic Medical Sciences2008-38662008-38742022-12-0125121477148610.22038/ijbms.2022.67038.1470121218In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexateSeyed Masih Adyani0Hamid Rashidzadeh1Mahdi Behdani2Seyed Jamal Tabatabaei Rezaei3Ali Ramazani4Pharmaceutical Biomaterials Department, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, IranPharmaceutical Biomaterials Department, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, IranDepartment of Molecular Medicine, Pasture Institute of Iran, Tehran, IranDepartment of Chemistry, University of Zanjan, Zanjan, IranCancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, IranObjective(s): In this study, Boltorn® H40-PEG-MTX-anti-VEGFR2 nanobody was fabricated in which nanobody was selected for blocking the receptor, H40 as a nanocarrier for delivery of methotrexate (MTX) to the tumor cells, and polyethylene glycol (PEG) moieties for improving the blood circulation time and safety. Materials and Methods: The synthesis process of the nanosystem has been characterized by different analytical methods. Results: The prepared nanoplatform exhibited high drug loading capacity, excellent colloidal stability, and an average particle size of around 105 nm. MTX was successfully conjugated through ester bonds and its release profile clearly showed that the ester bond is in favor of releasing the drug in acidic pH (5.5). The cytotoxicity of the developed nanoplatform exhibited great anti-cancer activity against MCF7 and KDR293 (cells with overexpressed anti-VEGFR2 NB receptors) cell lines while no deleterious toxicity was observed for nanocarrier against HEK293 normal cells. Furthermore, both hemolysis and LD50 assay results confirmed the hemocompatibility and biocompatibility of the developed nanoplatform. Conclusion: The most striking result to derive from the data is that the designed nanoplatform could potentially inhibit cell migration and invasion and the anti-angiogenesis properties of the developed nanoplatform may serve as a promising nanosystem to suppress the formation of blood vessels around tumor cells and consequently inhibit tumor progression.https://ijbms.mums.ac.ir/article_21218_94249941c8ac4e5e7cdc9eeb993f2010.pdfangiogenesis inhibitorsmethotrexatepolymersingle-domain antibodiesvascular endothelial - growth factor receptor-2 |
| spellingShingle | Seyed Masih Adyani Hamid Rashidzadeh Mahdi Behdani Seyed Jamal Tabatabaei Rezaei Ali Ramazani In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate Iranian Journal of Basic Medical Sciences angiogenesis inhibitors methotrexate polymer single-domain antibodies vascular endothelial - growth factor receptor-2 |
| title | In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
| title_full | In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
| title_fullStr | In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
| title_full_unstemmed | In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
| title_short | In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate |
| title_sort | in vitro evaluation of anti angiogenesis property of anti vegfr2 nanobody conjugated h40 peg carrier loaded with methotrexate |
| topic | angiogenesis inhibitors methotrexate polymer single-domain antibodies vascular endothelial - growth factor receptor-2 |
| url | https://ijbms.mums.ac.ir/article_21218_94249941c8ac4e5e7cdc9eeb993f2010.pdf |
| work_keys_str_mv | AT seyedmasihadyani invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT hamidrashidzadeh invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT mahdibehdani invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT seyedjamaltabatabaeirezaei invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate AT aliramazani invitroevaluationofantiangiogenesispropertyofantivegfr2nanobodyconjugatedh40pegcarrierloadedwithmethotrexate |